Tapentadol as a drug of abuse - A preliminary report.

IF 1.7 4区医学 Q3 PSYCHIATRY

Indian Journal of Psychiatry Pub Date : 2025-02-01 Epub Date: 2025-02-19 DOI:10.4103/indianjpsychiatry.indianjpsychiatry_794_24

Prakrithi Shivaprakash, Lekhansh Shukla, Sourabh Joshi, Jayant Mahadevan, Arun Kandasamy, Prabhat K Chand, Vivek Benegal, Pratima Murthy

{"title":"Tapentadol as a drug of abuse - A preliminary report.","authors":"Prakrithi Shivaprakash, Lekhansh Shukla, Sourabh Joshi, Jayant Mahadevan, Arun Kandasamy, Prabhat K Chand, Vivek Benegal, Pratima Murthy","doi":"10.4103/indianjpsychiatry.indianjpsychiatry_794_24","DOIUrl":null,"url":null,"abstract":"Background: Tapentadol is a dual action opioid analgesic with emerging data on abuse and diversion.Aim: This study describes tapentadol abuse, clinical presentation, and treatment patterns.Methods: We reviewed patients seeking help for tapentadol use (2017-2023) at a South Indian tertiary hospital. We collected data on sociodemographics, clinical profiles, and treatment, including buprenorphine dose and dose limiting side effects.Results: Of 933 opioid use disorder cases, 228 involved tapentadol. Most (89%) initiated opioid use with tapentadol, and 93% injected dissolved tablets. 80% were diagnosed with opioid dependence. Over half required inpatient treatment. 75% received buprenorphine, but tolerability was poor. The median first day dose was 0.8 mg (IQR = 0.4-2), and the maintenance dose was 4 mg (IQR = 2-8), with nausea being the main side effect.Conclusion: We can conclude that Tapentadol is prone to abuse and dependence. These patients have poor buprenorphine tolerability and receive low maintenance doses. Further research is needed on effective opioid agonist treatment for tapentadol dependence.","PeriodicalId":13345,"journal":{"name":"Indian Journal of Psychiatry","volume":"67 2","pages":"256-259"},"PeriodicalIF":1.7000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11964174/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4103/indianjpsychiatry.indianjpsychiatry_794_24","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/19 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Tapentadol is a dual action opioid analgesic with emerging data on abuse and diversion.

Aim: This study describes tapentadol abuse, clinical presentation, and treatment patterns.

Methods: We reviewed patients seeking help for tapentadol use (2017-2023) at a South Indian tertiary hospital. We collected data on sociodemographics, clinical profiles, and treatment, including buprenorphine dose and dose limiting side effects.

Results: Of 933 opioid use disorder cases, 228 involved tapentadol. Most (89%) initiated opioid use with tapentadol, and 93% injected dissolved tablets. 80% were diagnosed with opioid dependence. Over half required inpatient treatment. 75% received buprenorphine, but tolerability was poor. The median first day dose was 0.8 mg (IQR = 0.4-2), and the maintenance dose was 4 mg (IQR = 2-8), with nausea being the main side effect.

Conclusion: We can conclude that Tapentadol is prone to abuse and dependence. These patients have poor buprenorphine tolerability and receive low maintenance doses. Further research is needed on effective opioid agonist treatment for tapentadol dependence.

查看原文本刊更多论文

他他多是一种滥用药物-初步报告。

背景：他他多是一种双作用阿片类镇痛药，滥用和转移的数据正在出现。目的：本研究描述了他他多滥用、临床表现和治疗模式。方法：我们回顾了2017-2023年在南印度一家三级医院寻求他他多使用帮助的患者。我们收集了社会人口统计学、临床概况和治疗方面的数据，包括丁丙诺啡剂量和剂量限制副作用。结果：933例阿片类药物使用障碍中，228例涉及他他多。大多数（89%）开始与他他多一起使用阿片类药物，93%注射溶解片剂。80%被诊断为阿片类药物依赖。超过一半的患者需要住院治疗。75%的患者接受丁丙诺啡治疗，但耐受性差。第一天中位剂量为0.8 mg (IQR = 0.4-2)，维持剂量为4mg (IQR = 2-8)，主要副作用为恶心。结论：他他多有滥用和依赖倾向。这些患者丁丙诺啡耐受性差，维持剂量低。阿片受体激动剂治疗他他多依赖性的有效性有待进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Indian Journal of Psychiatry Medicine-Psychiatry and Mental Health

CiteScore

4.40

自引率

3.20%

发文量

130

审稿时长

34 weeks

期刊介绍： The Indian Journal of Psychiatry (ISSN 0019-5545), is an official publication of the Indian Psychiatric Society. It is published Bimonthly with one additional supplement (total 5 issues). The IJP publishes original work in all the fields of psychiatry. All papers are peer-reviewed before publication. The issues are published Bimonthly. An additional supplement is also published annually. Articles can be submitted online from www.journalonweb.com . The journal provides immediate free access to all the published articles. The journal does not charge the authors for submission, processing or publication of the articles.